Epigenetic Drug Therapy Based on Bromodomain Inhibition

References

• Filippakopoulos P , KnappS . Targeting bromodomains: epigenetic readers of lysine acetylation . Nat. Rev. Drug Discov.13 ( 5 ), 337 – 356 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gallenkamp D , GelatoKA , HaendlerBet al. Bromodomains and their pharmacological inhibitors . Chem. Med. Chem.9 ( 3 ), 438 – 464 ( 2014 ).
   Google Scholar
• Shi J , VakocCR . The mechanisms behind the therapeutic activity of BET bromodomain inhibition . Mol. Cell54 ( 5 ), 728 – 736 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lovén J , HokeHA , LinCYet al. Selective inhibition of tumor oncogenes by disruption of super-enhancers . Cell153 ( 2 ), 320 – 334 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hnisz D , AbrahamBJ , LeeTIet al. Super-enhancers in the control of cell identity and disease . Cell155 ( 4 ), 934 – 947 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Meng S , ZhangL , TangYet al. BET inhibitor JQ1 blocks inflammation and bone destruction . J. Dent. Res.93 ( 7 ), 657 – 662 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tang X , PengR , PhillipsJEet al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis . Am. J. Pathol.183 ( 2 ), 470 – 479 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lamoureux F , Baud’huinM , Rodriguez CallejaLet al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle . Nat. Commun.5 , 355 ( 2014 ).
   Web of Science ®Google Scholar
• Michaeloudes C , MercadoN , ClarkeCet al. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression . J. Immunol.192 ( 10 ), 4913 – 4920 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hussong M , BörnoST , KerickMet al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response . Cell Death Dis.5 , e1195 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ray S , ZhaoY , JamaluddinMet al. Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis . Cell Signal.26 ( 7 ), 1445 – 1455 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Liu S , WalkerSR , NelsonEAet al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2 . Mol. Cancer Ther.13 ( 5 ), 1194 – 1205 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Trabucco SE , GersteinRM , EvensAMet al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma . Clin. Cancer Res. ( 2014 ) ( In Press ).
   PubMed Web of Science ®Google Scholar
• Stewart HJ , HorneGA , BastowSet al. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1 . Cancer Med.2 ( 6 ), 826 – 835 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Henssen A , ThorT , OderskyAet al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma . Oncotarget4 ( 11 ), 2080 – 2095 ( 2013 ).
   PubMedGoogle Scholar
• Da Costa D , AgathanggelouA , PerryTet al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia . Blood Cancer J.3 , e126 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Roderick JE , TesellJ , ShultzLDet al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells . Blood123 ( 7 ), 1040 – 1050 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Loosveld M , CastellanoR , GonSet al. Therapeutic targeting of c-Myc in T-Cell acute lymphoblastic leukemia, T-ALL . Oncotarget5 ( 10 ), 3168 – 3172 ( 2014 ).
   PubMedGoogle Scholar
• Fiskus W , SharmaS , QiJet al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells . Mol. Cancer Ther.13 ( 5 ), 1142 – 1154 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tang Y , GholaminS , SchubertSet al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition . Nat. Med.20 ( 7 ), 732 – 740 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gallagher SJ , MijatovB , GunatilakeDet al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151 . Pigment Cell Melanoma Res. ( 2014 ) ( In Press ).
   Web of Science ®Google Scholar
• Barrett E , BrothersS , WahlestedtCet al. I-BET151 selectively regulates IL-6 production . Biochim. Biophys. Acta1842 ( 9 ), 1549 – 1555 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chaidos A , CaputoV , GouvedenouKet al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 . Blood123 ( 5 ), 697 – 705 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wyspiańska BS , BannisterAJ , BarbieriIet al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms . Leukemia28 ( 1 ), 88 – 97 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pastori C , DanielM , PenasCet al. BET bromodomain proteins are required for glioblastoma cell proliferation . Epigenetics9 ( 4 ), 611 – 620 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wyce A , DegenhardtY , BaiYet al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer . Oncotarget4 ( 12 ), 2419 – 2429 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zhao Y , YangCY , WangS . The making of I-BET762, a BET bromodomain inhibitor now in clinical development . J. Med. Chem.56 ( 19 ), 7498 – 7500 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Picaud S , WellsC , FelletarIet al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain . Proc. Natl Acad. Sci. USA110 ( 49 ), 19754 – 19759 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jahagirdar R , ZhangH , AzharSet al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice . Atherosclerosis236 ( 1 ), 91 – 100 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gacias M , Gerona-NavarroG , PlotnikovANet al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression . Chem. Biol.21 ( 7 ), 841 – 854 ( 2014 ).
   PubMedGoogle Scholar
• Bhadury J , NilssonLM , Veppil MuralidharanSet al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma . Proc. Natl Acad. Sci. USA111 ( 26 ), E2721 – E2730 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Devaiah BN , LewisBA , ChermanNet al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain . Proc. Natl Acad. Sci. USA109 ( 18 ), 6927 – 6932 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wang R , LiQ , HelferCMet al. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure . J. Biol. Chem.287 , 10738 – 10752 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Martin MP , OlesenSH , GeorgGIet al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains . ACS Chem. Biol.8 ( 11 ), 2360 – 2365 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ember SW , ZhuJY , OlesenSHet al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors . ACS Chem. Biol.9 ( 5 ), 1160 – 1171 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dittmann A , WernerT , ChungCWet al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains . ACS Chem. Biol.9 , 495 – 502 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Muvva C , SingamER , RamanSSet al. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors . Mol. Biosyst.10 ( 9 ), 2384 – 2397 ( 2014 ).
   PubMedGoogle Scholar
• Liu R , ZhongY , LiXet al. Role of transcription factor acetylation in diabetic kidney disease . Diabetes63 ( 7 ), 2440 – 2453 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Moros A , RodríguezV , Saborit-VillarroyaIet al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma . Leukemia doi:10.1038/eu.2014.106 ( 2014 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar